About: Use of tocilizumab in kidney transplant recipients with COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Use of tocilizumab in kidney transplant recipients with COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Use of tocilizumab in kidney transplant recipients with COVID‐19
Creator	Pascual, Julio María, \| Amir, \| Blasco, Miquel Carlos, \| Juan, \| Ventura-Aguiar, Pedro Canal, Cristina Galeano, Cristina Luis, \| Tabernero, Guadalupe Alex Gutiérrez-Dalmau, \| Auxiliadora Mazuecos, \| Bada-Bosch, Teresa Cabezas, J Crespo, \| Emilio Sánchez-Álvarez, \| Fernández-Reyes, J Garra-Moncau, Núria Jordi Espí-Reig, \| José Pérez-Sáez, María Leónidas Cruzado-Vega, \| Llinàs-Mallol, Laura Lourdes Pérez-Tamajón, \| López-Oliva, O Martín-Moreno, L Melilli, \| Paloma, \| Pérez-Flores, Isabel Pérez-Sáez, María Redondo-Pachón, Dolores Rodrigo, T Román Hernández-Gallego, \| Ruiz, C Ruiz-Fuentes, C Santana-Estupiñán, Raquel Siverio, \| Sofía Zárraga, \| Sánchez-Cámara, A Verónica López, \|
Source	Medline; PMC
abstract	Acute respiratory distress syndrome associated with coronavirus infection is related to a cytokine storm with large interleukin‐6 (IL‐6) release. The IL‐6‐receptor blocker tocilizumab may control the aberrant host immune response in patients with coronavirus disease 2019 (COVID‐19) . In this pandemic, kidney transplant (KT) recipients are a high‐risk population for severe infection and showed poor outcomes. We present a multicenter cohort study of 80 KT patients with severe COVID‐19 treated with tocilizumab during hospital admission. High mortality rate was identified (32.5%), related with older age (hazard ratio [HR] 3.12 for those older than 60 years, P = .039). IL‐6 and other inflammatory markers, including lactic acid dehydrogenase, ferritin, and D‐dimer increased early after tocilizumab administration and their values were higher in nonsurvivors. Instead, C‐reactive protein (CRP) levels decreased after tocilizumab, and this decrease positively correlated with survival (mean 12.3 mg/L in survivors vs. 33 mg/L in nonsurvivors). Each mg/L of CRP soon after tocilizumab increased the risk of death by 1% (HR 1.01 [confidence interval 1.004‐1.024], P = .003). Although patients who died presented with worse respiratory situation at admission, this was not significantly different at tocilizumab administration and did not have an impact on outcome in the multivariate analysis. Tocilizumab may be effective in controlling cytokine storm in COVID‐19 but randomized trials are needed.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1111/ajt.16192
bibo:pmid	32654422
has license	no-cc
sha1sum (hex)	2cef05e5fb3fdc69b25badad010fc43f453221ab
schema:url	https://doi.org/10.1111/ajt.16192
resource representing a document's title	Use of tocilizumab in kidney transplant recipients with COVID‐19
has PubMed Central identifier	PMC7405397
has PubMed identifier	32654422
schema:publication	Am J Transplant
resource representing a document's body	covid:2cef05e5fb3fdc69b25badad010fc43f453221ab#body_text
is schema:about of	named entity 'COVID-19' named entity 'Use' named entity 'COVID' named entity 'tocilizumab' named entity 'confidence interval' named entity 'risk of death' named entity 'Declaration of Helsinki' named entity 'respiratory disease' named entity 'acute respiratory distress syndrome' named entity 'C-reactive protein' named entity 'kidney transplant' named entity 'Spain' named entity 'follow-up' named entity 'tocilizumab' named entity 'humanized antibody' named entity 'C-reactive protein' named entity 'COVID-19 pandemic' named entity 'tocilizumab' named entity 'pharmacological' named entity 'tocilizumab' named entity 'mechanical ventilation' named entity 'Obesity' named entity 'fever' named entity 'tocilizumab' named entity 'infection' named entity 'IL-6' named entity 'hazard ratio' named entity 'receiver operating characteristic' named entity 'SPSS' named entity 'Respiratory symptoms' named entity 'body weight' named entity 'evolution' named entity 'multivariate analysis' named entity 'COVID' named entity 'ICU' named entity 'COVID' named entity 'CRP' named entity 'epidemiological' named entity 'Acute respiratory distress syndrome' named entity 'Tocilizumab' named entity 'Chicago' named entity 'SPSS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software